Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CLRB
CLRB logo

CLRB Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Cellectar Biosciences Inc (CLRB) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
2.790
1 Day change
12.50%
52 Week Range
13.950
Analysis Updated At
2026/06/12
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

CLRB is not a good buy right now for a Beginner long-term investor with $50,000-$100,000 available. The stock is extremely oversold and technically stretched, but the overall trend is still bearish, and there is no strong proprietary buy signal. For an impatient investor, this is not an attractive immediate entry. The better call is to hold off rather than buy at this point.

Technical Analysis

The technical picture is weak despite oversold conditions. RSI_6 at 15.962 shows the stock is deeply oversold, but MACD histogram is -0.0921 and still negatively expanding, which confirms downside momentum remains active. The moving average structure is bearish with SMA_200 > SMA_20 > SMA_5, showing the stock is in a downtrend. Price at 2.2587 is slightly below S1 at 2.302 and above S2 at 2.056, so it is trading near support but not yet showing a clear reversal. Based on the pattern data, near-term odds remain negative for the next day and week.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is not useful for bullish confirmation here. Put-call ratios are zero, with very low activity and only 5 call open interest, 0 put open interest, and 0 trading volume. That suggests extremely thin options participation and no strong market conviction. IV is very high at 500 with IV rank 65.55, which implies the market is pricing in large uncertainty.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
5
Buy
6

Positive Catalysts

  • ["Ladenburg initiated coverage with a Buy rating and $10 price target.", "Roth Capital kept a Buy rating and noted positive 12-month Phase 2 data for iopofosine I 131 in Waldenstrom macroglobulinemia.", "The company has a potential catalyst from a planned Phase 3 initiation in Q4 and possible accelerated approval filing path.", "The stock is technically oversold, which could support a rebound if buying interest returns."]

Neutral/Negative Catalysts

  • ["No news in the recent week, so there is no fresh near-term catalyst driving the shares.", "Analyst price target was cut from $14 to $11 by Roth Capital, showing reduced upside expectations.", "Hedge funds are neutral with no meaningful accumulation trend over the last quarter.", "Insiders are neutral with no significant buying signal over the last month.", "No recent congress trading data is available.", "No recent politician or influential figure buying or selling activity was reported."]

Financial Performance

No usable financial snapshot was provided because the data returned an error, so latest-quarter revenue, earnings, and growth trends cannot be assessed. The only available fundamental development is the clinical update, which is encouraging but is not the same as operating financial strength. For a beginner long-term investor, the lack of financial visibility makes the case weaker.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst sentiment is still constructive but slightly less aggressive than before. On 2026-05-15, Ladenburg assumed coverage with a Buy rating and a $10 target. On 2026-05-05, Roth Capital maintained a Buy rating but lowered its target to $11 from $14, indicating some moderation in expectations despite positive Phase 2 data. Overall, Wall Street pros remain bullish on the story, but the reduced target shows more cautious upside estimates than before.

Wall Street analysts forecast CLRB stock price to rise
Analyst Rating
0
Wall Street analysts forecast CLRB stock price to rise
Buy
Hold
Sell
0
Current: 2.480
sliders
Low
0
Averages
0
High
0
0
Current: 2.480
sliders
Low
0
Averages
0
High
0
Ladenburg
Buy
initiated
$10
AI Analysis
2026-05-15
Reason
Ladenburg
Price Target
$10
AI Analysis
2026-05-15
initiated
Buy
Reason
Ladenburg assumed coverage of Cellectar Biosciences with a Buy rating and $10 price target.
Roth Capital
Jonathan Aschoff
Buy
to
Buy
downgrade
$14 -> $11
2026-05-05
Reason
Roth Capital
Jonathan Aschoff
Price Target
$14 -> $11
2026-05-05
downgrade
Buy
to
Buy
Reason
Roth Capital analyst Jonathan Aschoff lowered the firm's price target on Cellectar Biosciences to $11 from $14 and keeps a Buy rating on the shares. Cellectar Biosciences reported positive 12-month Phase 2 data for iopofosine I 131 in Waldenstrom macroglobulinemia, demonstrating durable responses across patient groups and supporting the potential for an accelerated approval filing ahead of a planned Phase 3 initiation in Q4, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CLRB
Unlock Now

People Also Watch